Subcutaneous heparin during coronary thrombolysis. Too little, too late.
نویسندگان
چکیده
منابع مشابه
Niger: too little, too late.
Niger—with the world’s fastest growing population, its highest total fertility rate (TFR), a small and diminishing amount of arable land, low annual rainfall, a high level of malnutrition, extremely low levels of education, gross gender inequities and an uncertain future in the face of climate change—is the most extreme example of a catastrophe that is likely to overtake the Sahel. The policies...
متن کاملNRC proposed amendments: too little, too late?
the Nuclear Regulatory Com mission (NRC) by the Society ofNuclear Medicine and the American College ofNuclear Physiciansover four years ago is finally getting some response. The reaction from the peti tion's original author, however, has been less than favorable. Carol S. Marcus, PhD, MD, Director of Nuclear Medicine and Outpatient Clinic atHarbor-UCLAMedicalCenter and the principalauthorof the...
متن کاملReducing Cardiovascular Risk: Too Little, Too Late, Too Short-Term
Vascular diseases in general, and cardiovascular disease in particular, are diseases of mass destruction, killing more people in the Western world (and increasingly in the developing world) than world wars. Each year, coronary heart disease kills over half a million Americans and over 100 000 British citizens each year, often prematurely (WHO online). A combination of migration, epidemiological...
متن کاملWhat a difference a year makes? Too little too late.
'… if we could successfully intervene and change a woman's age at first birth and n oth in g else about her up to that point'? 1 Scally argu es th at we do n ot deal with th e m u ch m ore im port-an t issu es of th e edu cation al an d social effects of early m oth er-h ood an d focu s on a n arrow m edical defin ition of pu blic h ealth. We wou ld argu e th at we deal prim arily with th e det...
متن کاملIntrathecal baclofen in multiple sclerosis: too little, too late?
The majority of patients with multiple sclerosis (MS) have symptoms of spasticity that increasingly impair function as the disease progresses. With appropriate treatment, however, quality of life can be improved. Oral antispasticity medications are useful in managing mild spasticity but are frequently ineffective in controlling moderate to severe spasticity, because patients often cannot tolera...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 1992
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.86.5.1636